Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, MasterCard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Diğerleri
TradFi
Rewards
PFE

Pfizer Price

PFE
$27,17
-$0,66(-%2,37)

*Data last updated: 2026-04-07 19:46 (UTC+8)

As of 2026-04-07 19:46, Pfizer (PFE) is priced at $27,17, with a total market cap of $153,89B, a P/E ratio of 18,21, and a dividend yield of %6,35. Today, the stock price fluctuated between $26,78 and $27,60. The current price is %1,45 above the day's low and %1,55 below the day's high, with a trading volume of 11,08M. Over the past 52 weeks, PFE has traded between $21,97 to $28,74, and the current price is -%5,46 away from the 52-week high.

PFE Key Stats

Yesterday's Close$27,83
Market Cap$153,89B
Volume11,08M
P/E Ratio18,21
Dividend Yield (TTM)%6,35
Dividend Amount$0,43
Diluted EPS (TTM)1,36
Net Income (FY)$7,77B
Revenue (FY)$62,57B
Earnings Date2026-05-05
EPS Estimate0,77
Revenue Estimate$13,89B
Shares Outstanding5,52B
Beta (1Y)0.388
Ex-Dividend Date2026-01-23
Dividend Payment Date2026-03-06

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOAlbert Bourla
HeadquartersNew York City,NY,US
Official Websitehttps://www.pfizer.com
Employees (FY)75,00K
Average Revenue (1Y)$834,38K
Net Income per Employee$103,60K

Pfizer (PFE) FAQ

What's the stock price of Pfizer (PFE) today?

x
Pfizer (PFE) is currently trading at $27,17, with a 24h change of -%2,37. The 52-week trading range is $21,97–$28,74.

What are the 52-week high and low prices for Pfizer (PFE)?

x

What is the price-to-earnings (P/E) ratio of Pfizer (PFE)? What does it indicate?

x

What is the market cap of Pfizer (PFE)?

x

What is the most recent quarterly earnings per share (EPS) for Pfizer (PFE)?

x

Should you buy or sell Pfizer (PFE) now?

x

What factors can affect the stock price of Pfizer (PFE)?

x

How to buy Pfizer (PFE) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

PFE
CFD
Trade

Hot Posts About Pfizer (PFE)

GateUser-bd883c58

GateUser-bd883c58

03-30 08:08
This report (chinatimes.net.cn) reporter Hu Yawen reports from Beijing An increasing number of new energy companies must face the implications of the U.S. “Inflation Reduction Act.” Should they abandon the North American market or rebuild their overseas structure? Rongbai Technology (688005.SH) has chosen the latter. On March 17, Rongbai Technology announced plans to reduce the Chinese ownership ratio of its wholly-owned subsidiary in South Korea to below 25% through a series of operations, including equity transfers, to gain Non-PFE (non-prohibited foreign entity) status, thereby revitalizing the capacity of its South Korean ternary cathodes, which has accumulated an investment of 2.472 billion yuan. As of the time of publication, a reporter from the “Hua Xia Times” had sent inquiries to Rongbai Technology regarding related issues but had not received a response. This transaction involves the establishment of a joint venture by Rongbai Technology and its actual controller, Bai Houshan, the repayment of the South Korean subsidiary's 1.088 billion yuan in existing debt, and the protection of Rongbai Technology's future interests in the North American market. Well-known tax and accounting expert and senior certified public accountant Liu Zhigeng told a reporter from the “Hua Xia Times,” “This transaction is formally a premium sale, but overall it resembles a strategic divestiture of loss-making assets to avoid policy risks. The core goal is to adjust equity to make Singapore AKB the Non-PFE entity, thereby restoring supply qualifications in the North American market.” **Survival and Loss Prevention** In 2013, Laishi Energy Co., Ltd. (hereinafter referred to as “Korean JS”) was established as a wholly-owned subsidiary of Rongbai Technology, representing an investment of 2.472 billion yuan to create an overseas production base for cathode materials. Korean JS has successively built high-nickel ternary cathode production capacities of 27,000 tons and 40,000 tons per year, specifically targeting the North American market. Additionally, there are supporting capacities for ternary precursors and investment layouts aimed at the European market. However, the “Inflation Reduction Act” stipulates that enterprises in which Chinese entities hold more than 25% are classified as “prohibited foreign entities” (PFE). Once identified as such, North American customers will be unable to apply for tax incentives for purchasing PFE products. This directly weakens the competitiveness of Chinese enterprises in the North American market. Rongbai Technology stated, “The ternary capacity established in South Korea cannot effectively supply the Chinese and European markets due to economic reasons and the EU’s localization production requirements, and can only target the North American market. However, the company will lose all North American customers due to its PFE status, ultimately leading to idle capacity, continuous losses for Korean JS, asset impairment, and other damages to the company's interests.” Singapore AKB will replace Korean JS as the new entity to take on actual assets. Bai Houshan and Rongbai Technology established Singapore AKB and Korean AKB (a wholly-owned subsidiary of Singapore AKB) by the end of 2025. The announcement revealed that Rongbai Technology plans to split Korean JS into two entities, Korean JS Old and Korean JS New. Among them, Korean JS Old will hold a ternary cathode capacity of 7,000 tons/year and plans to transfer 31% and 69% equity of Korean JS Old to Singapore AKB and Korean AKB, respectively. The pricing for this transaction has not yet been finalized, but the announcement clearly states that the transaction price will have a certain premium based on the net asset assessment value of Korean JS Old and will not be less than the initial investment cost of fixed assets, with the assessment value expected to exceed $9 million (approximately 620 million yuan). As of the end of 2025, the cumulative investment amount for related assets is $6.8 million, with depreciation of $800,000 already accounted for since its use began in 2024. It is noteworthy that before asset delivery, Korean JS Old needs to repay a total of 1.088 billion yuan in payables to Rongbai Technology. Liu Zhigeng detailed the composition of this debt for reporters: the 1.088 billion yuan in payables consists mainly of two parts, with 91 million yuan being accounts payable arising from daily purchases (such as materials and equipment), and 997 million yuan being funds provided by the parent company for loans, management support, and R&D advances, among other non-trade transactions. Regarding the source of funds for repayment, Liu Zhigeng stated, “The funds for debt repayment do not rely on the operating cash flow of Korean JS Old (which has idle capacity due to PFE restrictions) but come directly from the equity transfer payments made by Singapore AKB and Korean AKB. The transaction funds will fully flow back to the listed company before asset delivery, ensuring a closed loop for debt repayment.” After the relevant transaction involving Korean JS Old is completed, Korean AKB will gradually purchase the remaining ternary cathode capacity owned by Korean JS New based on financing progress. Ultimately, Singapore AKB will take over the current ternary capacity of 67,000 tons/year held by Korean JS as a Non-PFE and will conduct North American business. Rongbai Technology will hold a 24.9% equity stake in Singapore AKB, enabling it to share its operating profit under the equity method in the future. **How to Ensure Voice?** Behind Singapore AKB is the actual controller of Rongbai Technology, Bai Houshan. In the past year, Rongbai Technology and Bai Houshan established a joint venture company, Singapore AKB, in collaboration with Amkobay Holding Pte. Ltd. (hereinafter referred to as “Singapore Company”). Rongbai Technology invested 124,500 Singapore dollars (approximately 680,000 yuan) in Singapore AKB through Korean JS, corresponding to an equity ratio of 24.9%; the Singapore Company invested 375,500 Singapore dollars (approximately 2.01 million yuan), corresponding to an equity ratio of 75.1%. This means that after this transaction, the core North American business will enter a structure controlled by Bai Houshan with 75.1% of Singapore AKB. Subsequently, Singapore AKB will also introduce third-party overseas investors and battery funds, and the proposed battery fund will become the main shareholder of Singapore AKB. For Rongbai Technology, after the transaction is completed, it will only hold a minority stake of 24.9% in Singapore AKB. Under the leadership of the actual controller and with the potential for new investors to be introduced later, how can Rongbai Technology ensure its voice? Liu Zhigeng stated that as a minority shareholder of Singapore AKB, Rongbai Technology's voice does not depend on its shareholding ratio but is realized through contractual rights in the shareholder agreement (SHA). The core protection mechanism of this agreement includes board seats, veto rights on major matters, rights to information and audits, rights of first refusal, and anti-dilution protection, “These terms are standard SPV governance practices internationally, especially in the new energy sector, where Chinese enterprises commonly adopt such structures when establishing Non-PFE entities overseas. Although the announcement did not disclose the specific agreement text, the statement that ‘fully protects the interests of minority shareholders’ implicitly indicates the existence of such contractual arrangements.” From a revenue perspective, after the adjustment of the Korean asset equity, Rongbai Technology's future sources of income will include one-time equity transfer payments and ongoing operational profits derived from the equity method. However, sustainable revenue depends on the profitability of Singapore AKB, and whether Singapore AKB can successfully penetrate the North American market and respond to ongoing changes in U.S. policy remains uncertain. In the past two years, Korean JS has continued to incur losses. In 2024 and 2025, Korean JS's operating revenues are projected to be 684 million yuan and 1.277 billion yuan, respectively; the net profits excluding non-recurring items are projected to be -206 million yuan and -163 million yuan, respectively. Rongbai Technology stated, “Last year, Korean JS's operating revenue accounted for 10.41% of the company's total revenue, with a net profit of -164 million yuan. This adjustment in the Korean business will not have a significant adverse impact on the company. After the adjustment, Singapore AKB and its subsidiaries will be strictly limited to conducting cathode material business in the North American market, while Rongbai Technology will be strictly limited to other non-North American regional markets, ensuring clear business boundaries and independent customer structures for both parties.” From a strategic perspective, this equity adjustment is a proactive measure by Rongbai Technology to address uncertainties; however, this transaction still faces multiple risks. The announcement warns that if policies related to the “Inflation Reduction Act” change, or if other relevant policies in the North American market are adjusted, the effects of the equity adjustment may fall short of expectations. Editor: Li Weilai Chief Editor: Zhang Yuning
0
0
0
0
MaticHoleFiller

MaticHoleFiller

03-20 07:12
Chinatimes.net.cn Reporter Hu Yawen Beijing Report An increasing number of new energy companies are facing the impact of the U.S. "Big and Beautiful Act." Should they give up the North American market or rebuild their overseas structure? Rongbai Technology (Rights Protection) (688005.SH) has chosen the latter. On March 17, Rongbai Technology announced plans to transfer equity and carry out a series of operations to reduce the Chinese shareholding in its wholly owned Korean subsidiary to below 25%, thereby obtaining Non-PFE (Non-Prohibited Foreign Entity) status. This move aims to revitalize the capacity of Korea Sanyuan Cathode and other production lines, which have a total investment of 2.472 billion yuan. As of March 17, a Huaxia Times reporter had sent a letter to Rongbai Technology regarding related issues, but no response had been received by press time. This transaction involves Rongbai Technology and its actual controller Bai Houshan jointly establishing a joint venture, addressing how to settle the 1.088 billion yuan debt of the Korean subsidiary, and safeguarding future interests in the North American market. Liu Zhigeng, a renowned tax and finance expert and senior CPA, told Huaxia Times, “On the surface, this is a premium sale, but overall, it resembles a strategic divestment of loss assets and risk avoidance. The core goal is to adjust equity to make Singapore AKB a Non-PFE entity, thereby restoring supply qualification in North America.” Seeking to Stop Loss In 2013, Jash Energy Co., Ltd. (hereafter "Korea JS") was established as a wholly owned subsidiary of Rongbai Technology, serving as the overseas cathode material production base built with an investment of 2.472 billion yuan. Korea JS has successively built annual capacities of 27,000 tons and 40,000 tons of high-nickel ternary cathodes, specifically targeting the North American market. It also has supporting ternary precursor capacity and investments aimed at the European market. However, the "Big and Beautiful Act" stipulates that Chinese entities holding more than 25% of shares are deemed "Prohibited Foreign Entities" (PFE). Once classified as such, North American customers purchasing PFE products cannot apply for tax subsidies. This directly weakens Chinese companies' competitiveness in the North American market. Rongbai Technology stated, “The ternary capacity built in Korea cannot effectively supply China or Europe due to economic reasons and EU localization requirements, and can only serve the North American market. However, the company will lose all North American customers due to PFE status, ultimately leading to idle capacity, continued losses for Korea JS, and asset impairments, damaging company interests.” Singapore AKB will replace Korea JS as the new entity, taking over the actual assets. Bai Houshan and Rongbai Technology have established two companies—Singapore AKB and Korea AKB (a wholly owned subsidiary of Singapore AKB)—by the end of 2025. The announcement shows Rongbai Technology plans to split Korea JS into two entities: Korea JS Old and Korea JS New. Korea JS Old will hold a capacity of 7,000 tons/year of ternary cathodes and plans to transfer 31% and 69% of its equity respectively to Singapore AKB and Korea AKB. The transaction price has not yet been finalized, but the announcement clearly states that the price will be based on the net asset valuation of Korea JS Old, with a certain premium, and not less than the initial investment in fixed assets. The valuation is expected to exceed $90 million (about 620 million yuan). By the end of 2025, related assets have a total investment of $68 million, with $8 million of depreciation since commissioning in 2024. It is noteworthy that before asset delivery, Korea JS Old must settle a total payable of 1.088 billion yuan to Rongbai Technology. Liu Zhigeng explained in detail that this payable mainly consists of two parts: 91 million yuan in accounts payable for daily procurement (materials, equipment), and 997 million yuan as loans, management support, and R&D advances provided by the parent company, which are non-trade-related. Regarding the source of repayment funds, Liu Zhigeng said, “The repayment does not rely on Korea JS Old’s own operating cash flow (which is limited due to PFE restrictions causing idle capacity), but directly comes from the transfer payments made by Singapore AKB and Korea AKB. These funds will be fully returned to the listed company before the asset transfer, ensuring the completion of debt repayment.” After the transaction with Korea JS Old is completed, Korea AKB will gradually purchase the remaining ternary capacity owned by Korea JS New according to financing progress. Ultimately, Singapore AKB will serve as a Non-PFE entity holding the current 67,000 tons/year capacity of Korea JS and will develop North American business. Rongbai Technology will hold a 24.9% stake in Singapore AKB, with subsequent profit sharing based on the equity method. How to Safeguard Voice? Behind Singapore AKB is Rongbai Technology’s actual controller Bai Houshan. Over the past year, Rongbai Technology and Bai Houshan jointly established Amkobay Holding Pte. Ltd. (the “Singapore company”) and set up the joint venture Singapore AKB. Rongbai Technology invested 124,500 SGD (about 680,000 yuan) into Korea JS to hold 24.9% of the equity; the Singapore company invested 375,500 SGD (about 2.01 million yuan) into Singapore AKB for a 75.1% stake. This means that after the transaction, the core North American business will be under the control of the Singapore AKB system, in which Bai Houshan holds 75.1%. Subsequently, Singapore AKB will also introduce third-party overseas investors and battery funds, with the planned battery fund becoming the main shareholder of Singapore AKB. For Rongbai Technology, after the transaction, it will only hold a 24.9% minority stake in Singapore AKB. Under the control of the actual controller and with potential new investors, how will Rongbai Technology safeguard its influence? Liu Zhigeng stated that Rongbai Technology’s minority stake in Singapore AKB does not depend on shareholding percentage but is secured through contractual rights in the Shareholders’ Agreement (SHA). The core protections include board seats, veto rights on major decisions, information rights, audit rights, tag-along rights, and anti-dilution protections. “These clauses are standard governance practices for SPVs internationally, especially in the new energy sector. When Chinese companies establish non-PFE entities overseas, they commonly adopt such structures. Although the specific agreement texts are not publicly disclosed, the statement of ‘full protection of minority shareholders’ interests’ implies the existence of such contractual arrangements.” From a revenue perspective, after the Korea asset restructuring, Rongbai Technology’s future income will include a one-time transfer payment and ongoing operating income from the equity method. However, the sustainability of income depends on the profitability of Singapore AKB, and whether Singapore AKB can successfully expand into the North American market and respond to ongoing U.S. policy changes remains uncertain. Over the past two years, Korea JS has continued to incur losses. In 2024 and 2025, Korea JS’s revenue was 684 million yuan and 1.277 billion yuan, respectively; net profit (excluding non-recurring gains/losses) was -206 million yuan and -163 million yuan. Rongbai Technology stated, “Last year, Korea JS’s revenue accounted for 10.41% of the company’s total revenue, with a net loss of 164 million yuan. This adjustment to Korea’s business will not significantly impact the company. Post-adjustment, Singapore AKB and its subsidiaries will strictly limit their cathode material business to North America, while Rongbai Technology will focus on other non-North American markets. The business boundaries are clear, and customer structures are independent.” Strategically, this equity adjustment is Rongbai Technology’s proactive response to uncertainties. However, the transaction still faces multiple risks. The announcement warns that if policies related to the "Big and Beautiful Act" change or other North American policies are adjusted, the effect of the equity restructuring may fall short of expectations. Editor: Li Weilai Chief Editor: Zhang Yuning
0
0
0
0
loki_season

loki_season

02-06 19:52
$PFE +7% ✅
0
0
0
0